GlassScriptPhysician profile
David Mittleman
NPI 1508818345
$40,775.33
in general payments reported to CMS, 2019-2025
44 companies · $3,525 in 2025
The $3,525 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,695 · 2020: $3,067 · 2021: $6,123 · 2022: $5,278 · 2023: $4,606 · 2024: $15K · 2025: $3,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $9,542 · Travel and Lodging: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,200.00 |
| Food and Beverage | $9,542.24 |
| Travel and Lodging | $1,871.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $20,477.68 | 2019-2025 | Lensx, Ora System Verifeye, Clareon |
| Carl Zeiss Meditec USA, INC. | $4,457.26 | 2021-2024 | Artevo 800, Veracity Surgical, Visumax |
| Alcon Research LLC | $2,800.00 | 2022 | |
| Allergan, INC. | $2,622.71 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $1,089.36 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $1,017.27 | 2022-2025 | Miebo, Xiidra, Envista Envy Iol |
| Johnson & Johnson Surgical Vision, INC. | $932.86 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Abbvie INC. | $828.14 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $739.26 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $574.91 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| New World Medical,INC. | $437.31 | 2022-2023 | |
| Dompe US, INC. | $401.79 | 2020-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $398.63 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $341.85 | 2019-2021 | |
| Harrow Eye, LLC | $308.14 | 2024-2025 | Vevye, Triesence, Iheezo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $272.57 | 2019-2021 | |
| Omeros Corporation | $260.40 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $258.85 | 2019-2021 | |
| Ivantis, INC | $230.01 | 2019-2020 | |
| Lumenis Be INC | $207.87 | 2025 | M22 |
| Ocular Therapeutix, INC. | $204.68 | 2020-2023 | Dextenza |
| Rxsight INC | $183.02 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Lombart Brothers, INC. | $181.83 | 2023 | Opd-III |
| Rayner Intraocular Lenses Limited | $178.64 | 2022 | |
| Mallinckrodt Hospital Products INC. | $164.63 | 2021-2022 | |
| Shire North American Group INC | $141.29 | 2019 | |
| Horizon Therapeutics Plc | $124.89 | 2021 | |
| Carl Zeiss Meditec, INC. | $121.77 | 2019 | |
| Coopervision INC. | $103.26 | 2022-2025 | Myday Contact Lens |
| Apellis Pharmaceuticals, INC. | $103.07 | 2023-2024 | Syfovre |
| Dutch Ophthalmic, USA | $96.20 | 2023 | Eva, Combined Machine, Tissueblue |
| Regeneron Healthcare Solutions, INC. | $80.21 | 2021-2022 | |
| Genentech USA, INC. | $76.86 | 2024-2025 | Vabysmo |
| Johnson & Johnson Vision Care, INC. | $65.37 | 2025 | |
| Lensar, INC. | $58.03 | 2023 | Lensar Laser System |
| Ani Pharmaceuticals, INC. | $52.76 | 2024 | Purified Cortrophin Gel |
| Oculus Surgical INC. | $48.71 | 2024 | |
| Glaukos Corporation | $32.27 | 2019-2021 | |
| Carl Zeiss Meditec Cataract Technology INC. | $26.31 | 2023 | |
| Iridex Corporation | $25.48 | 2019 | |
| Smith+Nephew, INC. | $20.00 | 2020 | |
| Oyster Point Pharma, INC. | $17.37 | 2025 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $11.81 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mittleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.